Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Reform Should Promote Industry: LDP Diet Member
February 25, 2002
- Matsumotokiyoshi Ties Up with Shimizu Yakuhin
February 25, 2002
- PFSB to Computerize All Administrative Procedures in FY2003
February 25, 2002
- Suzuken: New Blood Pressure Monitors
February 25, 2002
- Medical Institutions Should Join Discussions on Distribution Reform: Mr Matsutani of FJPWA
February 25, 2002
- Bio Media: New Sprayer for Sterilization
February 25, 2002
- Yamanouchi Expects 50% of Its Asian Sales in China
February 25, 2002
- AstraZeneca: Sales Up 8% to US$16,480 Mil.
February 25, 2002
- JPMA to Continue to Demand Better Protection of NDA Dossiers
February 25, 2002
- Quintiles: 4th Qtr Sales US$404 Million
February 25, 2002
- ICH ETWG Compiles Q&A for Implementation of CTD
February 25, 2002
- Sanofi-Synthelabo, Organon Launch Arixtra in US
February 25, 2002
- Hayashibara's IFN-a to Be Approved in South Korea
February 18, 2002
- REGULATORY NEWS IN BRIEF
February 18, 2002
- Japanese Global Strategy Update (7)
February 18, 2002
- Slowdown of Buying Activities Not Seen in Market
February 18, 2002
- Kusuri Proverbs Reveal Japanese Spirit (3)
February 18, 2002
- Chugai Transfers Marketing Rights of Keiten to Fujisawa
February 18, 2002
- Drug Makers Should Conclude Labor Contracts with Hospitals for PMS: Pharmacy Expert
February 18, 2002
- Novartis Transfers Marketing Rights for Halospor to Toyama
February 18, 2002
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…